Physician profile
Toni C Stockton
NPI 1972565109
$11,848.89
in general payments reported to CMS, 2019-2025
38 companies · $2,521 in 2025
The $2,521 reported for 2025 was more than what 89% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $368 · 2021: $602 · 2022: $908 · 2023: $2,079 · 2024: $4,817 · 2025: $2,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,198 · Travel and Lodging: $1,420 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $498 · Education: $266 · Gift: $33.57.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,198.34 |
| Travel and Lodging | $1,420.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $498.00 |
| Education | $265.75 |
| Gift | $33.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,947.98 | 2019-2025 | Botox, Rinvoq, Kybella |
| Janssen Biotech, INC. | $816.40 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Galderma Laboratories, L.P. | $717.35 | 2020-2025 | Nemluvio, Dysport, Aklief |
| Leo Pharma INC. | $522.43 | 2019-2025 | Anzupgo, Adbry |
| Arcutis Biotherapeutics, INC. | $487.93 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $458.07 | 2023-2024 | Vtama |
| Ucb, INC. | $435.91 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $409.88 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $362.26 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $344.10 | 2021-2025 | |
| Allergan, INC. | $308.94 | 2019-2022 | |
| Genzyme Corporation | $273.34 | 2021-2025 | |
| Dermira, INC. | $183.19 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $174.55 | 2019-2025 | |
| Amgen INC. | $174.26 | 2022-2025 | Otezla, Otezla |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Toni Stockton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.